Viewing Study NCT00807859

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 3:04 PM
Ignite Modification Date: 2026-02-02 @ 6:47 PM
Study NCT ID: NCT00807859
Status: COMPLETED
Last Update Posted: 2022-11-08
First Post: 2008-12-11
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Safety Study of AMG 386 to Treat HER2-positive Locally Recurrent or Metastatic Breast Cancer
Sponsor: Amgen
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Breast Cancer View
None Breast Neoplasms View
None Breast Tumors View
None Cancer View
None Locally Recurrent and Metastatic Breast Cancer View
None Metastases View
None Metastatic Cancer View
None Oncology View
None Solid Tumors View
None Tumors View
Keywords:

Keywords

Keyword Brief Keyword Text View
None AMG 386 View
None Paclitaxel View
None Trastuzumab View
None Capecitabine View
None Lapatinib View
None HER2-positive View
None metastatic breast cancer View
None locally recurrent breast cancer View
None Taxol View
None Herceptin View
None Xeloda View
None Tykerb View
None anti-angiogenic therapy View